Article
Oppenheimer Initiates Coverage On Evommune with Outperform Rating, Announces Price Target of $42
Oppenheimer analyst Andreas Argyrides initiates coverage on Evommune (NYSE:EVMN) with a Outperform rating and announces Price Target of $42.
Comments
- No comments yet. Be the first to comment!